US Pharma MarketingThe post Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial appeared first on Clinical Trials Arena.
Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial
Novo Nordisk is investigating ziltivekimab in two other studies, one in heart failure and one in patients who have experienced an acute heart attack. The post Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial appeared first on Clinical Trials Arena .
Novo Nordisk is investigating ziltivekimab in two other studies, one in heart failure and one in patients who have experienced an acute heart attack.
Source: Clinical Trials Arena